The impact of prehospital tranexamic acid on mortality and transfusion requirements: match-pair analysis from the nationwide German TraumaRegister DGU®.
Adult
Aged
Blood Transfusion
/ statistics & numerical data
Cohort Studies
Emergency Medical Services
/ methods
Female
Germany
Glasgow Coma Scale
Humans
Injury Severity Score
Male
Middle Aged
Mortality
/ trends
Prospective Studies
Registries
/ statistics & numerical data
Tranexamic Acid
/ administration & dosage
Bleeding
Coagulopathy
Hemostatic disorders
Mass transfusion
TXA
Tranexamic acid
Trauma
Trauma care
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
04 08 2021
04 08 2021
Historique:
received:
25
03
2021
accepted:
20
07
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Outcome data about the use of tranexamic acid (TXA) in civilian patients in mature trauma systems are scarce. The aim of this study was to determine how severely injured patients are affected by the widespread prehospital use of TXA in Germany. The international TraumaRegister DGU® was retrospectively analyzed for severely injured patients with risk of bleeding (2015 until 2019) treated with at least one dose of TXA in the prehospital phase (TXA group). These were matched with patients who had not received prehospital TXA (control group), applying propensity score-based matching. Adult patients (≥ 16) admitted to a trauma center in Germany with an Injury Severity Score (ISS) ≥ 9 points were included. The matching yielded two comparable cohorts (n = 2275 in each group), and the mean ISS was 32.4 ± 14.7 in TXA group vs. 32.0 ± 14.5 in control group (p = 0.378). Around a third in both groups received one dose of TXA after hospital admission. TXA patients were significantly more transfused (p = 0.022), but needed significantly less packed red blood cells (p ≤ 0.001) and fresh frozen plasma (p = 0.023), when transfused. Massive transfusion rate was significantly lower in the TXA group (5.5% versus 7.2%, p = 0.015). Mortality was similar except for early mortality after 6 h (p = 0.004) and 12 h (p = 0.045). Among non-survivors hemorrhage as leading cause of death was less in the TXA group (3.0% vs. 4.3%, p = 0.021). Thromboembolic events were not significantly different between both groups (TXA 6.1%, control 4.9%, p = 0.080). This is the largest civilian study in which the effect of prehospital TXA use in a mature trauma system has been examined. TXA use in severely injured patients was associated with a significantly lower risk of massive transfusion and lower mortality in the early in-hospital treatment period. Due to repetitive administration, a dose-dependent effect of TXA must be discussed.
Sections du résumé
BACKGROUND
Outcome data about the use of tranexamic acid (TXA) in civilian patients in mature trauma systems are scarce. The aim of this study was to determine how severely injured patients are affected by the widespread prehospital use of TXA in Germany.
METHODS
The international TraumaRegister DGU® was retrospectively analyzed for severely injured patients with risk of bleeding (2015 until 2019) treated with at least one dose of TXA in the prehospital phase (TXA group). These were matched with patients who had not received prehospital TXA (control group), applying propensity score-based matching. Adult patients (≥ 16) admitted to a trauma center in Germany with an Injury Severity Score (ISS) ≥ 9 points were included.
RESULTS
The matching yielded two comparable cohorts (n = 2275 in each group), and the mean ISS was 32.4 ± 14.7 in TXA group vs. 32.0 ± 14.5 in control group (p = 0.378). Around a third in both groups received one dose of TXA after hospital admission. TXA patients were significantly more transfused (p = 0.022), but needed significantly less packed red blood cells (p ≤ 0.001) and fresh frozen plasma (p = 0.023), when transfused. Massive transfusion rate was significantly lower in the TXA group (5.5% versus 7.2%, p = 0.015). Mortality was similar except for early mortality after 6 h (p = 0.004) and 12 h (p = 0.045). Among non-survivors hemorrhage as leading cause of death was less in the TXA group (3.0% vs. 4.3%, p = 0.021). Thromboembolic events were not significantly different between both groups (TXA 6.1%, control 4.9%, p = 0.080).
CONCLUSION
This is the largest civilian study in which the effect of prehospital TXA use in a mature trauma system has been examined. TXA use in severely injured patients was associated with a significantly lower risk of massive transfusion and lower mortality in the early in-hospital treatment period. Due to repetitive administration, a dose-dependent effect of TXA must be discussed.
Identifiants
pubmed: 34348782
doi: 10.1186/s13054-021-03701-7
pii: 10.1186/s13054-021-03701-7
pmc: PMC8336395
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma Acute Care Surg. 2006;60(6):S3–11.
doi: 10.1097/01.ta.0000199961.02677.19
Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma Acute Care Surg. 2003;54(6):1127–30.
doi: 10.1097/01.TA.0000069184.82147.06
Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury. 2007;38(3):298–304.
pubmed: 17214989
doi: 10.1016/j.injury.2006.10.003
Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma. Crit Care. 2019;23(1):98.
pubmed: 30917843
pmcid: 6436241
doi: 10.1186/s13054-019-2347-3
Cannon JW, Khan MA, Raja AS, et al. Damage control resuscitation in patients with severe traumatic hemorrhage: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2017;82(3):605–17.
pubmed: 28225743
doi: 10.1097/TA.0000000000001333
Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1: 1: 1 vs a 1: 1: 2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, J Am Med Assoc. 2015;313(5):471–82.
doi: 10.1001/jama.2015.12
Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma Acute Care Surg. 2007;63(4):805–13.
doi: 10.1097/TA.0b013e3181271ba3
Albrecht V, Schäfer N, Stürmer E, et al. Practice management of acute trauma haemorrhage and haemostatic disorders across German trauma centres. Eur J Trauma Emerg Surg. 2017;43(2):201–14.
pubmed: 26619853
doi: 10.1007/s00068-015-0608-7
Inaba K, Rizoli S, Veigas PV, et al. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: report of the panel. J Trauma Acute Care Surg. 2015;78(6):1220–9.
pubmed: 26151526
doi: 10.1097/TA.0000000000000657
Novak A, Stanworth SJ, Curry N. Do we still need cryoprecipitate? Cryoprecipitate and fibrinogen concentrate as treatments for major hemorrhage—how do they compare? Expert Rev Hematol. 2018;11(5):351–60.
pubmed: 29584463
doi: 10.1080/17474086.2018.1458610
Wafaisade A, Lefering R, Maegele M, et al. Coagulation management of bleeding trauma patients is changing in German trauma centers: an analysis from the trauma registry of the German Society for Trauma Surgery. J Trauma Acute Care Surg. 2012;72(4):936–42.
pubmed: 22491608
doi: 10.1097/TA.0b013e31823dca70
Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10(7):1342–51.
pubmed: 22519961
doi: 10.1111/j.1538-7836.2012.04752.x
Schöchl H, Frietsch T, Pavelka M, et al. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma Acute Care Surg. 2009;67(1):125–31.
doi: 10.1097/TA.0b013e31818b2483
Moore HB, Moore EE, Gonzalez E, et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6):811.
pubmed: 25051384
pmcid: 4370273
doi: 10.1097/TA.0000000000000341
Stein P, Studt J-D, Albrecht R, et al. The impact of prehospital tranexamic acid on blood coagulation in trauma patients. Anesth Analg. 2018;126(2):522–9.
pubmed: 29239953
doi: 10.1213/ANE.0000000000002708
Moore HB, Moore EE, Neal MD, et al. Fibrinolysis shutdown in trauma: historical review and clinical implications. Anesth Analg. 2019;129(3):762–73.
pubmed: 31425218
pmcid: 7340109
doi: 10.1213/ANE.0000000000004234
Moore HB, Moore EE, Huebner BR, et al. Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis. J Surg Res. 2017;220:438–43.
pubmed: 28755903
pmcid: 5677580
doi: 10.1016/j.jss.2017.04.028
Meizoso JP, Dudaryk R, Mulder MB, et al. Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid. J Trauma Acute Care Surg. 2018;84(3):426–32.
pubmed: 29298240
doi: 10.1097/TA.0000000000001792
Polytrauma Guideline Update Group. Level 3 guideline on the treatment of patients with severe/multiple injuries: AWMF Register-Nr. 012/019. Eur J Trauma Emerg Surg. 2018;44(Suppl 1):3–271.
doi: 10.1007/s00068-018-0922-y
Williams-Johnson J, McDonald A, Strachan GG, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. West Indian Med J. 2010;59(6):612–24.
pubmed: 21702233
CRASH-2 Collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. The Lancet. 2011;377(9771):1096–101.
doi: 10.1016/S0140-6736(11)60278-X
Wafaisade A, Lefering R, Bouillon B, et al. Prehospital administration of tranexamic acid in trauma patients. Crit Care. 2016;20(1):143.
pubmed: 27176727
pmcid: 4866028
doi: 10.1186/s13054-016-1322-5
Surgery TRotGSoT. ‘Scoring’study committee of the German Society of Trauma Surgery. Unfallchirurg. 1994;97:230–7.
Ruchholtz S, Lefering R, Lewan U, et al. Implementation of a nationwide trauma network for the care of severely injured patients. J Trauma Acute Care Surg. 2014;76(6):1456–61.
pubmed: 24854315
doi: 10.1097/TA.0000000000000245
Baker SP, o’Neill B, Haddon W Jr, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma Acute Care Surg. 1974;14(3):187–96.
doi: 10.1097/00005373-197403000-00001
Gennarelli T, Wodzin E. A contemporary injury scale Injury. Int J Care Injured. 2006;37:1083–91.
doi: 10.1016/j.injury.2006.07.009
Vincent J-L, De Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998;26(11):1793–800.
pubmed: 9824069
doi: 10.1097/00003246-199811000-00016
Rc BONE. Let’s agree on terminology: definitions of sepsis. Crit Care Med. 1991;19(7):973–6.
doi: 10.1097/00003246-199107000-00024
Lefering R, Huber-Wagner S, Nienaber U, et al. Update of the trauma risk adjustment model of the TraumaRegister DGU™: The Revised Injury Severity Classification, version II. Critical care (London, England). 2014;18:476.
doi: 10.1186/s13054-014-0476-2
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–34.
doi: 10.1080/03610910902859574
Neeki MM, Dong F, Toy J, et al. Safety and efficacy of hospital utilization of tranexamic acid in civilian adult trauma resuscitation. West J Emerg Med. 2020;21(2):217.
pubmed: 32191179
pmcid: 7081849
doi: 10.5811/westjem.2019.10.43055
Neeki MM, Dong F, Toy J, et al. Tranexamic acid in civilian trauma care in the California prehospital antifibrinolytic therapy study. West J Emerg Med. 2018;19(6):977.
pubmed: 30429930
pmcid: 6225940
doi: 10.5811/westjem.2018.8.39336
Shafi S, Collinsworth AW, Richter KM, et al. Bundles of care for resuscitation from hemorrhagic shock and severe brain injury in trauma patients—translating knowledge into practice. J Trauma Acute Care Surg. 2016;81(4):780–94.
pubmed: 27389129
doi: 10.1097/TA.0000000000001161
Almuwallad A, Cole E, Ross J, et al. The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2021;90(5):901–7.
pubmed: 33605702
doi: 10.1097/TA.0000000000003120
CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394:1713–23.
doi: 10.1016/S0140-6736(19)32233-0
Cole E, Davenport R, Willett K, et al. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg. 2015;261(2):390–4.
pubmed: 25412319
doi: 10.1097/SLA.0000000000000717
Jiménez JJ, Iribarren JL, Brouard M, et al. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg. 2011;6:138.
pubmed: 21999189
pmcid: 3206427
doi: 10.1186/1749-8090-6-138
Guyette FX, Brown JB, Zenati MS, et al. Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: a double-blind, placebo-controlled, randomized Clinical Trial. JAMA Surg. 2020;156:11–20.
pmcid: 7536625
pubmed: 7536625
Thorn S, Lefering R, Maegele M, et al. Early prediction of acute traumatic coagulopathy: a validation of the COAST score using the German Trauma Registry. Eur J Trauma Emerg Surg. 2021;47:333–41.
pubmed: 31037353
doi: 10.1007/s00068-019-01142-0
Gruen RL, Jacobs IG, Reade MC. Trauma and tranexamic acid. Med J Aust. 2013;199(5):310–1.
pubmed: 23992173
doi: 10.5694/mja13.10747
Lier H, Maegele M. Blutungsmanagement: Tranexamsäure in der Präklinik. Pro und Kontra. Notfall + Rettungsmedizin. 2019;22(8):685–95.
doi: 10.1007/s10049-018-0471-2
Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma. Crit Care. 2016;20(1):100.
pubmed: 27072503
pmcid: 4828865
doi: 10.1186/s13054-016-1265-x
Grassin-Delyle S, Theusinger O, Albrecht R, et al. Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. Anaesthesia. 2018;73(6):719–29.
pubmed: 29411358
doi: 10.1111/anae.14184
Johnston LR, Rodriguez CJ, Elster EA, et al. Evaluation of military use of tranexamic acid and associated thromboembolic events. JAMA Surg. 2018;153(2):169–75.
pubmed: 29071337
doi: 10.1001/jamasurg.2017.3821
Morrison JJ, Dubose JJ, Rasmussen TE, et al. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg. 2012;147(2):113–9.
pubmed: 22006852
doi: 10.1001/archsurg.2011.287
Roberts I, Shakur-Still H, Afolabi A, et al. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. The Lancet. 2020;395(10241):1927–36.
doi: 10.1016/S0140-6736(20)30848-5
Murkin JM, Falter F, Granton J, et al. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010;110(2):350–3.
pubmed: 19996135
doi: 10.1213/ANE.0b013e3181c92b23
Frimat M, Decambron M, Lebas C, et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis. 2016;68(1):50–7.
pubmed: 26786299
doi: 10.1053/j.ajkd.2015.11.022
Rowell SE, Meier EN, McKnight B, et al. Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury. JAMA. 2020;324(10):961–74.
pubmed: 32897344
pmcid: 7489866
doi: 10.1001/jama.2020.8958
Mellin-Olsen J, Staender S, Whitaker DK, et al. The Helsinki declaration on patient safety in anaesthesiology. Eur J Anaesthesiol. 2010;27(7):592–7.
pubmed: 20520556
doi: 10.1097/EJA.0b013e32833b1adf
Ditzel RM Jr, Anderson JL, Eisenhart WJ, et al. A review of transfusion-and trauma-induced hypocalcemia: is it time to change the lethal triad to the lethal diamond? J Trauma Acute Care Surg. 2020;88(3):434–9.
pubmed: 31876689
doi: 10.1097/TA.0000000000002570
Brown JB, Neal MD, Guyette FX, et al. Design of the study of tranexamic acid during air medical prehospital transport (STAAMP) trial: addressing the knowledge gaps. Prehosp Emerg Care. 2015;19(1):79–86.
pubmed: 25076119
doi: 10.3109/10903127.2014.936635